Category Specific RSS

pharmaxis

First cohort responds well to Pharmaxis cancer treatment drug – next phase of clinical trial fully subscribed

Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for…

4 years ago

Spray-on skin revenue exceeds initial forecasts

The inventors of “spray-on skin”, Avita Medical (ASX: AVH) have today released their financial results for the fiscal fourth quarter…

4 years ago

Karst backs Aussie small cap following hugely successful pharma strategy

Leading fund manager Karst Peak Capital has secured a significant interest in a little-known Aussie pharmaceuticals research company, following the…

4 years ago

Pharmaxis shares present untapped value as the drug developer pursues a rare cancer therapy

In biotech circles, tackling a rare and difficult disease with few patients does not necessarily equate to targeting an unprofitable…

4 years ago

Pharmaxis targeting scar-free recovery from burns with world-first trials

One of the world’s most respected surgeons in the field of burns and trauma recovery will lead world-first clinical trials…

4 years ago